Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Beijing Airdoc Technology Co (HKSE:02251) Cash Conversion Cycle Explanation
Generally, the lower this number is, the better for the company. Although it should be combined with other metrics (such as ROE % and ROA %), it can be especially useful for comparing close competitors, because the company with the lowest CCC is often the one with better management.
Be Aware
CCC is most effective with retail-type companies, which have inventories that are sold to customers. Consulting businesses, software companies and insurance companies are all examples of companies for whom this metric is meaningless.
The CCC is one of several tools that can help you evaluate management, especially if it is calculated for several consecutive time periods and for several competitors. Decreasing or steady CCCs are good, while rising ones should motivate you to dig a bit deeper.
Beijing Airdoc Technology Co Cash Conversion Cycle Related Terms
Beijing Airdoc Technology Co Cash Conversion Cycle Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Beijing Airdoc Technology Co Cash Conversion Cycle Chart
HKSE:02251 vs VEEV, BTSG, TEM: Cash Conversion Cycle Comparison
For the Health Information Services subindustry, Beijing Airdoc Technology Co's Cash Conversion Cycle, along with its competitors' market caps and Cash Conversion Cycle data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Beijing Airdoc Technology Co Cash Conversion Cycle vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Beijing Airdoc Technology Co's Cash Conversion Cycle distribution charts can be found below:
* The bar in red indicates where Beijing Airdoc Technology Co's Cash Conversion Cycle falls into.
Beijing Airdoc Technology Co Cash Conversion Cycle Calculation
Cash Conversion Cycle (CCC) measures how fast a company can convert cash on hand into even more cash on hand. This metric looks at the amount of time needed to sell inventory, the amount of time needed to collect receivables and the length of time the company is afforded to pay its bills without incurring penalties.
Cash Conversion Cycle is one of several measures of management effectiveness.
Beijing Airdoc Technology Co's Cash Conversion Cycle for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Beijing Airdoc Technology Co (HKSE:02251) has a Cash Conversion Cycle of 277.62 as of Dec. 2025. Cash conversion cycle equals sum of days inventory and days sales outstanding less days payable. View historical data on Beijing Airdoc Technology Co and its competitors.
Is Beijing Airdoc Technology Co's Cash Conversion Cycle too high?
Beijing Airdoc Technology Co's current Cash Conversion Cycle is 277.62. The Healthcare Providers & Services industry median Cash Conversion Cycle is 17.55. Beijing Airdoc Technology Co's value of 277.62 is 1481.9% above this industry median. Overall, Beijing Airdoc Technology Co has a GF Score™ of 64/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Beijing Airdoc Technology Co's Cash Conversion Cycle compare to VEEV and BTSG?
Beijing Airdoc Technology Co's Cash Conversion Cycle of 277.62 can be compared against companies in the Healthcare Providers & Services industry. The industry median Cash Conversion Cycle is 17.55. Beijing Airdoc Technology Co's value of 277.62 is 1481.9% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash Conversion Cycle for a Healthcare Providers & Services company?
The median Cash Conversion Cycle among Healthcare Providers & Services companies is 17.55, based on 667 companies in the industry. Companies in the top quartile (top 25%) have a Cash Conversion Cycle significantly above this median, while those in the bottom quartile fall well below. However, Cash Conversion Cycle should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Beijing Airdoc Technology Co's current Cash Conversion Cycle of 277.62 is 1481.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash Conversion Cycle mean?
A high Cash Conversion Cycle can signal that a stock is expensive relative to its fundamentals. Cash conversion cycle equals sum of days inventory and days sales outstanding less days payable. View historical data on Beijing Airdoc Technology Co and its competitors. For the Healthcare Providers & Services industry, the median Cash Conversion Cycle is 17.55 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Beijing Airdoc Technology Co's current Cash Conversion Cycle is 277.62. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Beijing Airdoc Technology Co stock overvalued right now?
Based on GuruFocus' analysis, Beijing Airdoc Technology Co (HKSE:02251) is currently considered Significantly Undervalued. The stock's GF Value™ is HK$15.18, compared to a current price of HK$7.90 — trading 48% below its estimated fair value. The current Cash Conversion Cycle is 277.62 and 1481.9% above the Healthcare Providers & Services industry median of 17.55. Beijing Airdoc Technology Co's overall GF Score™ is 64/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash Conversion Cycle calculated?
Cash Conversion Cycle is calculated from a company's financial statements. For Beijing Airdoc Technology Co (HKSE:02251), the current Cash Conversion Cycle is 277.62 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Beijing Airdoc Technology Co (HKSE:02251) Overvalued in 2026?
Based on GuruFocus' analysis, Beijing Airdoc Technology Co stock appears to be undervalued.
The current stock price of HK$7.90 is trading 48% below its estimated GF Value™ of HK$15.18.
GuruFocus considers Beijing Airdoc Technology Co to be Significantly Undervalued.
Key valuation signals for HKSE:02251:
Cash Conversion Cycle: 277.62
GF Value™: HK$15.18 vs. price of HK$7.90 (48% below fair value)
Industry Position: 1481.9% above the Healthcare Providers & Services median
No single metric tells the full story. See the HKSE:02251 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Beijing Airdoc Technology Co Ltd provides AI-empowered retina-based early detection, diagnosis, and health risk assessment solutions in China. Leveraging retinal imaging, multimodal data analyses, and AI deep learning algorithms, the company's solution differs from traditional chronic disease early detection and diagnosis, enabling non-invasive, accurate, fast, effective, and scalable detection and diagnosis of chronic diseases in both medical institutions and consumer healthcare providers. The Company derives revenue from the provision of AI-based software solutions, sales of hardware devices, and other services. Geographically, the company generates the majority of its revenue from Mainland China.
64GF Score
Get the complete analysis for HKSE:02251
Cash Conversion Cycle is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKSE:02251 has been successfully added to your 
